September 9th 2025
A manageable safety profile was observed across 2 expansion doses of the combination in urothelial cancer, consistent with known adverse effects of both drugs.
Combination of TKI, Anti-PD1 Agent Active in Metastatic RCC
September 12th 2017More than half of patients with metastatic clear cell renal cell carcinoma treated with a combination of lenvatinib and pembrolizumab responded to treatment at week 24, according to interim results of a phase I/II study presented at the 2017 ESMO Congress.
Benefits Vary With Docetaxel and Abiraterone in High-Risk Prostate Cancer
September 11th 2017The first head-to-head comparison of docetaxel and abiraterone acetate for high-risk prostate cancer patients starting long-term hormone therapy found benefit with both treatments when added to ADT. Treatment decisions may come down to specific toxicities, which differ between the treatments.
Analysis: Major Prostate Cancer Screening Trials Agree on Mortality Reduction
September 7th 2017An analysis that corrected for differences in implementation found that the two main trials of prostate cancer screening in Europe and the United States both show a reduction in prostate cancer mortality with screening.
Surgery in Early Prostate Cancer Did Not Significantly Reduce Mortality
July 13th 2017Long-term follow-up found no significant differences in all-cause or disease-related mortality in men with early prostate cancer randomized to either radical prostatectomy or to observation. Surgery led to more adverse events, but less treatment for disease progression.
Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications
June 15th 2017In this article, we look at both metastatic hormone-sensitive and metastatic castration-resistant disease, and we highlight several of the emerging categories of advanced prostate cancer that have direct implications for patient management.
Approved Bladder Cancer Drug Fails to Improve Survival in Confirmatory Trial
May 11th 2017An interim analysis of the phase III IMvigor211 study found that atezolizumab did not meet its primary endpoint of improving overall survival over chemotherapy in patients with locally advanced or metastatic urothelial cancer.